Shopping Cart
- Remove All
- Your shopping cart is currently empty
Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Ormutivimab (rhRIG), a recombinant human monoclonal antibody designed to target the rabies virus, effectively neutralizes various strains and demonstrates strong efficacy as a post-exposure prophylaxis (PEP) treatment in model studies [1] [2]. |
In vivo | Ormutivimab, at a single dose of 20 IU/kg administered via intramuscular injection, conferred protection to beagles against the lethal challenge of RABV BD06. Similarly, a single intramuscular injection of Ormutivimab, at dosages of 20 IU/kg and 100 IU/kg, provided protective immunity to Kunming mice subjected to various rabies virus strains. |
Alias | rhRIG, NM57 |
Cas No. | 2449086-91-1 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.